Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cerenis Therapeutics has completed a Phase I clinical trial for CER-002, a peroxisome proliferator-activated receptor delta-specific agonist in development for the treatment of cardiovascular diseases.
Subscribe to our email newsletter
The study was a randomized, double-blind, placebo-controlled, cross-over, single-rising dose study conducted with healthy male volunteers. Objectives of the study included assessments of the safety, tolerability, and pharmacokinetics of CER-002 when administered as a single dose, as well as the effect of food on single dose pharmacokinetics. Twenty-four subjects received CER-002. The product was found to be well tolerated and safe at all doses tested, without any serious adverse effects.
Jean-Louis Dasseux, president and CEO of Cerenis, said: “CER-002 is a novel compound which has shown significant antiatherosclerotic properties in animal models even at low doses. As we move forward with the clinical development program for CER-002, we will also continue planning clinical stage development programs for the other promising product candidates in our portfolio.”